PT  - JOURNAL ARTICLE
AU  - Ariën, Kevin K.
AU  - Heyndrickx, Leo
AU  - Michiels, Johan
AU  - Vereecken, Katleen
AU  - Van Lent, Kurt
AU  - Coppens, Sandra
AU  - Pannus, Pieter
AU  - Martens, Geert A.
AU  - Van Esbroeck, Marjan
AU  - Goossens, Maria E.
AU  - Marchant, Arnaud
AU  - Bartholomeeusen, Koen
AU  - Desombere, Isabelle
TI  - Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern
AID  - 10.1101/2021.12.23.21268316
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.23.21268316
4099  - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268316.short
4100  - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268316.full
AB  - We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in healthy individuals pre-infected or not with SARS-CoV-2 and immunized with three doses of the BNT162b2 vaccine. Our observations support the rapid administration of a booster vaccine dose to prevent infection and disease caused by Omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Belgian Federal Government through Sciensano (COVID-19_SC004, _SC049, _SC059, _SC103) and the Research Foundation Flanders (FWO G0G4220N).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee approvals from Hopital Erasme, Brussels, Belgium and AZ Delta, Roeselare, Belgium (for residual samples of hospitalized patients) are in place for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors